OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in HIV and AIDS is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The interplay between HIV and COVID-19: summary of the data and responses to date	136
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	70
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	46
A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV	40
Eliminating HIV reservoirs for a cure: the issue is in the tissue	38
Impact of Integrase inhibitors and tenofovir alafenamide on weight gain in people with HIV	33
Exosomes in HIV infection	26
Frailty: the current challenge for aging people with HIV	26
Cardiovascular toxicity of contemporary antiretroviral therapy	25
Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV	22
Immunological effector mechanisms in HIV-1 elite controllers	21
Clinical consequences of asymptomatic cytomegalovirus in treated human immunodeficency virus infection	19
The first 6 months of HIV-SARS-CoV-2 coinfection: outcomes for 6947 individuals	19
HIV persistence in lymph nodes	19
HIV and cardiovascular disease: the role of inflammation	18
Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	17
Technologies for HIV-1 drug resistance testing: inventory and needs	17
Scaling up preexposure prophylaxis to maximize HIV prevention impact	15
Adapting digital health interventions for the evolving HIV landscape: examples to support prevention and treatment research	15
The future of long-acting agents for preexposure prophylaxis	14
Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV	14
HIV care during the coronavirus disease-2019 pandemic in Shenzhen, China	14
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	14
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	13
Doravirine: its role in HIV treatment	13

The active human immunodeficiency virus reservoir during antiretroviral therapy: emerging players in viral persistence	12
The effect of HIV on COVID-19 vaccine responses	12
Broadly neutralizing antibodies for HIV treatment and cure approaches	11
New vector and vaccine platforms: mRNA, DNA, viral vectors	11
An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors	11
Molecular epidemiology in the HIV and SARS-CoV-2 pandemics	10
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
From surviving to thriving: the current status of the behavioral, social, and psychological issues of aging with HIV	10
“Go”, “No Go,” or “Where to Go”; does microbiota dictate T cell exhaustion, programming, and HIV persistence?	10
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	10
Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy: Republication	9
Recent data on adipose tissue, insulin resistance, diabetes and dyslipidaemia in antiretroviral therapy controlled HIV-infected persons	9
Cardiovascular disease risk in women living with HIV	9
Context, COVID-19 and comorbidities: exploring emergent directions in syndemics and HIV research	9
Promises and challenges: cabotegravir for preexposure prophylaxis	9
Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection	9
Role of islatravir in HIV treatment and prevention: an update	8
The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy	8
Long COVID in people living with HIV	8
Hidden in plain sight: sex and gender in global pandemics	8
Treatment of coronavirus disease 2019	8
Advances in cell and gene therapy for HIV disease: it is good to be specific	8
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	8
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	7
An exploration of how broadly neutralizing antibodies might induce HIV remission: the ‘vaccinal’ effect	7
Potential and demonstrated impacts of the COVID-19 pandemic on sexually transmissible infections: Republication	7
Chimeric antigen receptor T-cell therapy for HIV cure	7
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	7
Assessing proviral competence: current approaches to evaluate HIV-1 persistence	7
COVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research	7
Recent advances in HIV-associated chronic lung disease clinical research	7
Moving toward equity: fostering transdisciplinary research between the social and behavioral sciences and implementation science to end the HIV epidemic	7